Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2010

01-04-2010 | Preclinical study

Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells

Authors: Oliver Treeck, Claus Lattrich, Anette Springwald, Olaf Ortmann

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Login to get access

Abstract

Estrogen receptor β (ERβ) is widely expressed in mammary epithelium. ERβ expression is reported to decline during carcinogenesis of the breast and other tissues. In this study, we examined the consequences of a loss of ERβ expression in mammary epithelial cells. We knocked down ERβ transcript levels in human mammary epithelial MCF-10A cells and in MCF-7 breast cancer cells by means of stable transfection with a specific shRNA plasmid. ERβ knockdown resulted in a significant growth increase of both cell types in a ligand-independent manner. This effect was accompanied by elevated cyclin A2 expression in MCF-10A cells and by decreased expression of growth-inhibitory p21/WAF and epithelial cell marker cytokeratine 8 in both cell lines. Transfection of ERβ shRNA did not alter the absent proliferative estrogen response of MCF-10A cells, but conferred sensitivity to selective estrogen receptor modulator tamoxifen to this cell line. In contrast, ERβ knockdown diminished estrogen responsiveness of MCF-7 breast cancer cells and also weakened the effect of tamoxifen on this cell line. These ligand-dependent effects only observed in MCF-7 cells exhibiting a high ERα/β ratio were accompanied by smaller estrogenic repression of p21/WAF expression, an impaired tamoxifen-triggered induction of this gene and by relative downregulation of ERα and cyclin A2 transcript levels. Our data suggest that ERβ exerts antiproliferative effects both on MCF-10A and MCF-7 cells in a ligand- and ERα-independent manner by regulation of p21/WAF or cyclin A2 gene expression. Knockdown of ERβ in both cell types was sufficient to significantly decrease transcript levels of epithelial cell marker cytokeratin 8. The results of this study support the hypothesis that ERβ acts as a tumor suppressor in mammary epithelium.
Literature
3.
go back to reference Leygue E, Dotzlaw H, Watson P, Murphy L (1998) Altered estrogen receptor alpha and beta mRNA expression during human breast tumorigenesis. Cancer Res 58:3197–3201PubMed Leygue E, Dotzlaw H, Watson P, Murphy L (1998) Altered estrogen receptor alpha and beta mRNA expression during human breast tumorigenesis. Cancer Res 58:3197–3201PubMed
4.
go back to reference Jarvinen T, Pelto-Huikko M, Holli K, Isola J (2000) Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status grade and proliferation rate in breast cancer. Am J Pathol 156:29–35PubMed Jarvinen T, Pelto-Huikko M, Holli K, Isola J (2000) Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status grade and proliferation rate in breast cancer. Am J Pathol 156:29–35PubMed
5.
go back to reference Forster C, Makela S, Warri A, Kietz S, Becker D, Hultenby K, Warner M, Gustafsson J (2002) Involvement of estrogen receptor b in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci USA 99:15578–15583. doi:10.1073/pnas.192561299 CrossRefPubMed Forster C, Makela S, Warri A, Kietz S, Becker D, Hultenby K, Warner M, Gustafsson J (2002) Involvement of estrogen receptor b in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci USA 99:15578–15583. doi:10.​1073/​pnas.​192561299 CrossRefPubMed
6.
go back to reference Hall J, McDonnell D (1999) The estrogen receptor betaisoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140:5566–5578. doi:10.1210/en.140.12.5566 CrossRefPubMed Hall J, McDonnell D (1999) The estrogen receptor betaisoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140:5566–5578. doi:10.​1210/​en.​140.​12.​5566 CrossRefPubMed
9.
go back to reference Roger P, Sahla M, Makela S, Gustafsson JA, Baldet P, Rochefort H (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537–2541PubMed Roger P, Sahla M, Makela S, Gustafsson JA, Baldet P, Rochefort H (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537–2541PubMed
10.
go back to reference Dotzlaw H, Leygue E, Watson P, Murphy L (1999) Estrogen receptor-b messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. Cancer Res 59:529–532PubMed Dotzlaw H, Leygue E, Watson P, Murphy L (1999) Estrogen receptor-b messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. Cancer Res 59:529–532PubMed
12.
go back to reference Fuqua S, Schiff R, Parra I, Friedrichs W, Su J, McKee D, Slentz-Kesler K, Moore L, Willson T, Moore J (1999) Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res 59:5425–5428PubMed Fuqua S, Schiff R, Parra I, Friedrichs W, Su J, McKee D, Slentz-Kesler K, Moore L, Willson T, Moore J (1999) Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res 59:5425–5428PubMed
13.
go back to reference Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson J (2002) Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 62:4849–4853PubMed Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson J (2002) Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 62:4849–4853PubMed
14.
go back to reference Saji S, Omoto Y, Shimizu C, Horiguchi S, Watanabe T, Funata N, Hayash S, Gustafsson J, Toi M (2002) A Clinical impact of assay of estrogen receptor beta cx in breast cancer. Breast Cancer 9:303–307. doi:10.1007/BF02967608 CrossRefPubMed Saji S, Omoto Y, Shimizu C, Horiguchi S, Watanabe T, Funata N, Hayash S, Gustafsson J, Toi M (2002) A Clinical impact of assay of estrogen receptor beta cx in breast cancer. Breast Cancer 9:303–307. doi:10.​1007/​BF02967608 CrossRefPubMed
17.
go back to reference Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson J-A, Rochefort H (2004) Estrogen receptor beta (ERbeta) level but not its ERbeta-cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 10:5769–5776. doi:10.1158/1078-0432.CCR-04-0389 CrossRefPubMed Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson J-A, Rochefort H (2004) Estrogen receptor beta (ERbeta) level but not its ERbeta-cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 10:5769–5776. doi:10.​1158/​1078-0432.​CCR-04-0389 CrossRefPubMed
18.
go back to reference Fleming F, Hill A, McDermott E, O’Higgins N, Young L (2004) Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptorestrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. J Clin Endocrinol Metab 89:375–383. doi:10.1210/jc.2003-031048 CrossRefPubMed Fleming F, Hill A, McDermott E, O’Higgins N, Young L (2004) Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptorestrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. J Clin Endocrinol Metab 89:375–383. doi:10.​1210/​jc.​2003-031048 CrossRefPubMed
20.
go back to reference Skliris G, Munot K, Bell S, Carder P, Lane S, Horgan K, Lansdown M, Parkes A, Hanby A, Markham A, Speirs V (2003) Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyltransferase inhibitors in a cell line model. J Pathol 201:213–220. doi:10.1002/path.1436 CrossRefPubMed Skliris G, Munot K, Bell S, Carder P, Lane S, Horgan K, Lansdown M, Parkes A, Hanby A, Markham A, Speirs V (2003) Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyltransferase inhibitors in a cell line model. J Pathol 201:213–220. doi:10.​1002/​path.​1436 CrossRefPubMed
21.
go back to reference Treeck O, Juhasz-Boess I, Lattrich C, Horn F, Goerse R, Ortmann O (2008) Effects of exon-deleted estrogen receptor β transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines. Breast Cancer Res Treat 110(3):507–520. doi:10.1007/s10549-007-9749-7 CrossRefPubMed Treeck O, Juhasz-Boess I, Lattrich C, Horn F, Goerse R, Ortmann O (2008) Effects of exon-deleted estrogen receptor β transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines. Breast Cancer Res Treat 110(3):507–520. doi:10.​1007/​s10549-007-9749-7 CrossRefPubMed
22.
go back to reference Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64(1):423–428. doi:10.1158/0008-5472.CAN-03-2446 CrossRefPubMed Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64(1):423–428. doi:10.​1158/​0008-5472.​CAN-03-2446 CrossRefPubMed
23.
go back to reference Ståhlberg A, Åman P, Ridell B, Mostad P, Kubista M (2003) A quantitative real-time PCR method for detection of B-lymphocyte monoclonality by comparison of kappa and lambda immunoglobulin light chain expression. Clin Chem 49(1):51–59. doi:10.1373/49.1.51 CrossRefPubMed Ståhlberg A, Åman P, Ridell B, Mostad P, Kubista M (2003) A quantitative real-time PCR method for detection of B-lymphocyte monoclonality by comparison of kappa and lambda immunoglobulin light chain expression. Clin Chem 49(1):51–59. doi:10.​1373/​49.​1.​51 CrossRefPubMed
26.
go back to reference Soule HD et al (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial MCF- 10. Cancer Res 50:6075–6086PubMed Soule HD et al (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial MCF- 10. Cancer Res 50:6075–6086PubMed
27.
go back to reference Fuchs IB, Lichtenegger W, Buehler H, Henrich W, Stein H, Kleine-Tebbe A, Schaller G (2002) The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res 22(6A):3415–3419PubMed Fuchs IB, Lichtenegger W, Buehler H, Henrich W, Stein H, Kleine-Tebbe A, Schaller G (2002) The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res 22(6A):3415–3419PubMed
29.
go back to reference Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G (2008) Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26(22):3727–3734. doi:10.1200/JCO.2007.14.2968 CrossRefPubMed Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G (2008) Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26(22):3727–3734. doi:10.​1200/​JCO.​2007.​14.​2968 CrossRefPubMed
30.
go back to reference Hodges-Gallagher L, Valentine CD, El Bader S, Kushner PJ (2008) Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat 109(2):241–250. doi:10.1007/s10549-007-9640-6 CrossRefPubMed Hodges-Gallagher L, Valentine CD, El Bader S, Kushner PJ (2008) Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat 109(2):241–250. doi:10.​1007/​s10549-007-9640-6 CrossRefPubMed
Metadata
Title
Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells
Authors
Oliver Treeck
Claus Lattrich
Anette Springwald
Olaf Ortmann
Publication date
01-04-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0413-2

Other articles of this Issue 3/2010

Breast Cancer Research and Treatment 3/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine